Navigation Links
NextSource Biotechnology Launches New Strategic Approach to Mitigate Slow-Downs in Manufacturing of Matured Medications in High Demand
Date:9/23/2013

MIAMI, Sept. 23, 2013 /PRNewswire/ -- NextSource Biotechnology, LLC., (NSB), a leading Specialty Pharmaceutical Manufacturing and Marketing company with a strategic objective of Consolidating, Re-Branding and launching a "Matured & Orphan Drugs" product portfolio in the U.S. and International Healthcare Markets. By utilizing a worldwide distribution network as a key synergistic approach to aggressively build out our pipeline of products, we have aligned our plan with all regulatory requirements needed to gain expedited FDA approvals, Aligned Drug Portfolio selections and structured a plan to maximize production through our international globalization partnership.

The "Matured Drugs, Orphan Drugs and Discontinued Medications currently contribute to many of the existing deficiencies in all Healthcare Markets. These deficiencies have broadened the U.S. Healthcare Market's dependency on having to import over 80% of existing Prescription Medications from Manufacturers throughout the world.  In addition, due the discontinuation of many high value Matured Drugs; the Healthcare market has reached a record high in FDA Short Supply.  This problem has created a multi-billion dollar dependency on Non-FDA Approved Compounding Pharmacies.

At NSB, our goal is to ensure the Healthcare Markets continued access to these important medications. All products in the NSB portfolio share development factors that Cross Over the Human Healthcare market yielding additional indications for use in Companion Animals. These initiatives will optimize, secure and diversify the product portfolio yielding the highest revenue potential while maintaining the most secure supply chain.

"Due to current market conditions, "said Robert DiCrisci, President, CEO of NextSource Biotechnology, we are strategically positioned to launch a product portfolio that will further anchor our position as the leader in product re-branding and product diversification of the "Matured & Orphan Drugs". Our future remains focused on maximizing our existing portfolio of products, while maintaining flexibility to bring in additional products as demands change."

NSB's core competencies in marketing and business development enabled us to engage in high volume distribution agreements with the top Wholesalers in the US Market which currently account for high volume nationwide distribution on over 70% of our revenue.

NextSource Biotechnology recently re-introduced the Lomustine (CCNU) product formally known as CeeNu® through an exclusive manufacturing partnership with CordenPharma, Latina. This business development was the result of a divestiture between Bristol-Myers Squibb (BMS) and CordenPharma\NextSource Biotechnology. NSB is currently in the final stage of normalizing the shortage of Lomustine (formally known as CeeNu®) in the U.S. healthcare market. NSB is projected to be off short supply by the close of Q3, 2013. The medication will continue to be distributed under the Lomustine label pending FDA "Brand" name review and approval.  

Lomustine has been shown to be useful as a single agent in addition to other treatment modalities, or in established combination therapy with other approved chemotherapeutic agents in the following:

Brain tumors—both primary and metastatic, in patients who have already received appropriate surgical and/or radio therapeutic procedures.
Hodgkin's disease—secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.

About our Partner: CordenPharma is an expert Contract Manufacturing partner helping leading pharmaceutical and biotechnology companies link their requirements for product success with their patients' healthier lives.

Formed as a pharmaceutical branch of International Chemical Investors Group in 2006, CordenPharma provides specialized technologies that are ideal for the development and manufacturing of oral, sterile, highly potent and antibiotic pharmaceutical Drug Products, their Active Pharmaceutical Ingredients, and associated Global Supply Chain and Packaging Services.


'/>"/>
SOURCE NextSource Biotechnology
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Goodwin Biotechnology Announces the Appointment of SooYoung S. Lee, PhD as Chief Operating Officer
2. Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship
3. TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States
4. Cytos Biotechnology Ltd Reports Second Quarter 2013 Financial Results and Recent Developments
5. The Galien Foundation Announces 2013 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
6. ResearchMoz.us: Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing & Others) - Global Industry Analysis, Size, Share, Growt
7. Platine Pharma Services et Indicia Biotechnology se rapprochent pour renforcer leur leadership en immunomonitoring
8. Goodwin Biotechnology Announces Process Development Sub-Contract for an Anthrax Vaccine
9. Sony Biotechnology Inc.s New Technology for Science Provides Researchers Results in Color
10. Plandai Biotechnology, Inc. Announces Formation Of New Entity To Develop Pharmaceutical Applications
11. Increased Dosage of Needle-Free Erectile Dysfunction Medication TriMix-gel Now Available through KRS Global Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Texas , Feb. 12, 2016 On ... for Robotic Surgery at St. David,s North Austin Medical ... da Vinci ® Xi ® Surgical System ... 7000dV. Thiru Lakshman , M.D., colorectal ... a total proctocolectomy utilizing Integrated Table Motion technology, which ...
(Date:2/12/2016)... North Carolina , 12 februari 2016 ... Inc. (AAI/CML), een toonaangevende leverancier van productie ... en biotechnologische industrieën, kondigt vandaag een uitbreiding ... mogelijkheden op haar locatie in ... vraag heeft geleid tot meerdere recente investeringen. ...
(Date:2/11/2016)... Feb. 11, 2016 The primary goal of ... adoption patterns on the usage of liquid biopsy. Key ... - Timeframe of liquid biopsy adoption amidst ... and Evs—by organization type - Sample inflow to conduct ... saliva, stool, serum, and so on. - Correlation analysis ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... The National Association for Children ... organization representing the growing community of recovering individuals (now over 23 million), to ... in policies addressing addiction. , Although many of the presidential candidates of ...
(Date:2/13/2016)... , ... February 13, 2016 , ... The producers of ... of American businesses. , The increasingly modern world of instantaneous consumption proves very ... non-renewable energy sources such as oil and coal, which pollutes our air, water, and ...
(Date:2/13/2016)... , ... February 13, 2016 , ... When an Au Pair comes all ... sure what they are in for and they are often worried things won’t go well. ... were hoping for. This year’s Au Pair of the Year winner’s all commented how their ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article published ... for a significant portion of hernia repairs throughout the United States. Commenting on this ... Center notes that this trend has not only been expected, but it seems to ...
(Date:2/12/2016)... and Washington, DC (PRWEB) , ... ... ... and the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity ... low-resource settings. The partnership will recruit top students from U.S. universities who ...
Breaking Medicine News(10 mins):